blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3634997

EP3634997 - NOVEL ANTI-HSA ANTIBODIES [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  12.03.2021
Database last updated on 15.06.2024
FormerRequest for examination was made
Status updated on  13.03.2020
FormerThe international publication has been made
Status updated on  15.12.2018
Formerunknown
Status updated on  20.06.2018
Most recent event   Tooltip10.11.2023New entry: Reply to examination report 
Applicant(s)For all designated states
Numab Therapeutics AG
Einsiedlerstrasse 34
8820 Wädenswil / CH
[2020/16]
Inventor(s)01 / GUNDE, Tea
Turbinenstrasse 33
8005 Zurich / CH
02 / MEYER, Sebastian
Kirchrainstrasse 6
5445 Eggenwil / CH
03 / HESS, Christian
Uetlibergstrasse 304
8045 Zurich / CH
04 / BIERI, Tessa
Rue des Uttins 1D
1110 Morges / CH
[N/P]
Former [2020/16]01 / GUNDE, Tea
Turbinenstrasse 33
8005 Zurich / CH
02 / MEYER, Sebastian
Kirchrainstrasse 6
5445 Eggenwil / CH
03 / HESS, Christian
Uetlibergstrasse 304
8045 Zurich / CH
04 / BIERI, Tessa
Rue des Charpentiers 4
1110 Morges / CH
Representative(s)Wallinger Ricker Schlotter Tostmann
Patent- und Rechtsanwälte mbB
Zweibrückenstraße 5-7
80331 München / DE
[2020/16]
Application number, filing date18729642.104.06.2018
[2020/16]
WO2018EP64622
Priority number, dateUS201762515293P05.06.2017         Original published format: US 201762515293 P
EP2017019578310.10.2017         Original published format: EP 17195783
[2020/16]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018224439
Date:13.12.2018
Language:EN
[2018/50]
Type: A1 Application with search report 
No.:EP3634997
Date:15.04.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 13.12.2018 takes the place of the publication of the European patent application.
[2020/16]
Search report(s)International search report - published on:EP13.12.2018
ClassificationIPC:C07K16/18, C07K16/24
[2020/16]
CPC:
C07K16/18 (EP,IL,KR,US); C07K16/244 (EP,IL,KR); A61K2039/505 (KR);
C07K2317/24 (EP,IL,KR,US); C07K2317/31 (EP,IL,KR,US); C07K2317/33 (EP,IL,KR,US);
C07K2317/60 (EP,IL,KR); C07K2317/622 (EP,IL,KR,US); C07K2317/92 (EP,IL,KR,US);
C07K2317/94 (EP,IL,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/16]
Extension statesBA07.01.2020
ME07.01.2020
Validation statesKH07.01.2020
MA07.01.2020
MD07.01.2020
TN07.01.2020
TitleGerman:NEUARTIGE ANTI-HSA-ANTIKÖRPER[2020/16]
English:NOVEL ANTI-HSA ANTIBODIES[2020/16]
French:NOUVEAUX ANTICORPS ANTI-HSA[2020/16]
Entry into regional phase05.11.2019National basic fee paid 
05.11.2019Designation fee(s) paid 
05.11.2019Examination fee paid 
Examination procedure05.11.2019Examination requested  [2020/16]
05.11.2019Date on which the examining division has become responsible
07.08.2020Amendment by applicant (claims and/or description)
12.03.2021Despatch of a communication from the examining division (Time limit: M04)
22.07.2021Reply to a communication from the examining division
31.08.2023Despatch of a communication from the examining division (Time limit: M02)
10.11.2023Reply to a communication from the examining division
Fees paidRenewal fee
30.03.2020Renewal fee patent year 03
23.06.2021Renewal fee patent year 04
31.03.2022Renewal fee patent year 05
31.03.2023Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[IY]WO2010035012  (UCB PHARMA SA [BE], et al) [I] 1-15 * examples 11-13; claims 1-10; tables 12, 15, 17 * [Y] 1-15;
 [IY]WO2010094722  (GLAXO GROUP LTD [GB], et al) [I] 1-15 * claims 1-27; table 6 * [Y] 1-15;
 [IY]WO2010094723  (GLAXO GROUP LTD [GB], et al) [I] 1-15 * claims 1-28; table 6 * [Y] 1-15;
 [I]WO2011036460  (UCB PHARMA SA [BE], et al) [I] 1-13 * examples 1, 2,; tables 12, 15, 17, 23, 24 *;
 [IY]WO2013068571  (UCB PHARMA SA [BE]) [I] 1-15 * p 23, 2.2;; figures 7-13; example 3; claims 1-14 * [Y] 1-15;
 [A]WO2014206561  (NUMAB AG [CH]) [A] 1-15;
 [AD]WO2016202457  (NUMAB AG [CH]) [AD] 1-15;
 [IY]  - EMMA DAVÉ ET AL, "Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding", MABS, US, (20160817), vol. 8, no. 7, doi:10.1080/19420862.2016.1210747, ISSN 1942-0862, pages 1319 - 1335, XP055428628 [I] 1-15 * abstract * [Y] 1-15

DOI:   http://dx.doi.org/10.1080/19420862.2016.1210747
 [A]  - CHRISTIAN SCHRÖTER ET AL, "A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display", MABS, US, (20141218), vol. 7, no. 1, doi:10.4161/19420862.2014.985993, ISSN 1942-0862, pages 138 - 151, XP055428679 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.4161/19420862.2014.985993
 [A]  - TIMOTHY J. EGAN ET AL, "Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments", MABS, US, (20161027), vol. 9, no. 1, doi:10.1080/19420862.2016.1248012, ISSN 1942-0862, pages 68 - 84, XP055467772 [A] 1-15

DOI:   http://dx.doi.org/10.1080/19420862.2016.1248012
by applicantEP0404097
 WO9301161
 WO9957150
 US6703199
 WO2014206561
 WO2016202457
    - KOHLER; MILSTEIN, Nature, (19750000), vol. 256, pages 495 - 7
    - BINDER; SKERRA, Curr. Opin. Colloid Int., (20170000), vol. 31, pages 10 - 17
    - HOLT et al., Protein Engineering, Design and Selection, (20080000), vol. 21, pages 283 - 288
    - SUGIO, Protein Eng, (19990000), vol. 12, pages 439 - 446
    - FANALI, Molecular Aspects of Medicine, (20120000), vol. 33, pages 209 - 290
    - HOLLINGER; HUDSON, Nature Biotechnology, (20050000), vol. 23, pages 1126 - 1136
    - AL-LAZIKANI et al., JMB, (19970000), vol. 273, pages 927 - 948
    - LEFRANC, M.-P., The Immunologist, (19990000), vol. 7, pages 132 - 136
    - LEFRANC, M.-P. et al., Dev. Comp. Immunol., (20030000), vol. 27, pages 55 - 77
    - HONEGGER; PLUCKTHUN, J. Mol. Biol., (20010000), vol. 309, pages 657 - 670
    - HENIKOFF, S.; HENIKOFF, J. G., Proc. Natl. Acad. Sci. USA, (19920000), vol. 89, pages 10915 - 10919
    - KNAPPIK et al., J. Mol. Biol., (20000000), vol. 296, pages 57 - 86
    - SMITH; WATERMAN, Adv. Appl. Math., (19810000), vol. 2, page 482
    - NEEDLEMAN; WUNSCH, J. Mol. Biol., (19700000), vol. 48, pages 443 - 53
    - PEARSON; LIPMAN, Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, pages 2444 - 48
    - M.O. DAYHOFF; R. SCHWARTZ; B.C. ORCUTT, "A model of Evolutionary Change in Proteins", Atlas of protein sequence and structure, National Biomedical Research Foundation, (19790000), pages 345 - 352
    - EGAN et al., MAbs, (20170000), vol. 9, no. 1, pages 68 - 84
    - NIESEN et al., Nature Protocols, (20070000), vol. 2, no. 9, pages 2212 - 2221
    - WONG; RALEIGH, Protein Science, (20160000), vol. 25, pages 1834 - 1840
    - PLUCKTHUN, The pharmacology of Monoclonal Antibodies, Springer-Verlag, (19940000), vol. 113, pages 269 - 315
    - EGAN T. et al., mAbs, (20170000), vol. 9, pages 68 - 84
    - MAbs, (20170200), vol. 9, no. 2, pages 182 - 212
    - HUDSON et al., Nat. Med., (20030000), vol. 9, pages 129 - 134
    - HOLLINGER et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 6444 - 6448
    - FISCHER, N.; LEGER, O., Pathobiology, (20070000), vol. 74, pages 3 - 14
    - HORNIG, N.; FARBER-SCHWARZ, A., Methods Mol. Biol., (20120000), vol. 907, pages 713 - 727
    - LABRIJN et al., Proc. Natl. Acad. Sci. USA, (20130000), vol. 110, pages 5145 - 5150
    - DE KRUIF et al., Biotechnol. Bioeng., (20100000), vol. 106, pages 741 - 750
    - ZHU et al., Cancer Lett., (19940000), vol. 86, pages 127 - 134
    - SURESH et al., Methods Enzymol., (19860000), vol. 121, pages 210 - 228
    - CHAMES; BATY, FEMS Microbiol. Letters, (20000000), vol. 189, pages 1 - 8
    - BATZER et al., Nucleic Acid Res., (19910000), vol. 19, page 5081
    - OHTSUKA et al., J. Biol. Chem., (19850000), vol. 260, pages 2605 - 2608
    - ROSSOLINI et al., Mol. Cell. Probes, (19940000), vol. 8, pages 91 - 98
    - YU et al., "A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models", PLoS ONE, (20100000), vol. 5, no. 2, page e9072
    - BORRAS et al., J. Biol. Chem., (20100000), vol. 285, pages 9054 - 9066
    - HOLLIGER et al., "Diabodies'': small bivalent and bispecific antibody fragments", Proc. Natl. Acad. Sci. U.S.A., vol. 90, doi:doi:10.1073/pnas.90.14.6444, pages 6444 - 6448, XP002713413

DOI:   http://dx.doi.org/10.1073/pnas.90.14.6444
    - SAMBROOK, J. et al., Molecular Cloning: A Laboratory Manual
    - NIESEN et al., Nat Protoc., (20070000), vol. 2, pages 2212 - 21
    - SCHOONJANS, R.; A. WILLEMS; J. GROOTEN; N. MERTENS, "Efficient heterodimerization of recombinant bi- and trispecific antibodies", Bioseparation, (20000000), vol. 9, no. 3, doi:doi:10.1023/A:1008120203269, pages 179 - 183, XP001012944

DOI:   http://dx.doi.org/10.1023/A:1008120203269
    - SCHOONJANS, R.; A. WILLEMS; S. SCHOONOOGHE; W. FIERS; J. GROOTEN; N. MERTENS, "Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives", J Immunol, (20000000), vol. 165, no. 12, pages 7050 - 7057, XP002207879
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.